Pediatric Drugs

, Volume 15, Issue 2, pp 139–150

Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis

  • Noor B. Almandil
  • Ying Liu
  • Macey L. Murray
  • Frank M. C. Besag
  • Katherine J. Aitchison
  • Ian C. K. Wong
Systematic Review

Abstract

Objectives

The aims of this study were to provide a systematic review and meta-analysis of the effects of atypical antipsychotics in children and adolescents on weight gain (primary objective) and other metabolic parameters (secondary objective).

Methods

A systematic literature review and meta-analysis of double-blind, randomized, controlled trials were conducted. The data sources used were as follows: EMBASE, PubMed, BIOSIS, International Pharmaceutical Abstracts, The Cochrane database (Clinical Trials), Clinical Trials Government Registry, The metaRegister of Controlled Trials, WHO (World Health Organization) Clinical Trials Registry Platform, and PsycINFO®. Hand searching was also carried out by examining the reference lists of identified studies. Double-blind, randomized, controlled trials investigating the metabolic adverse effects (weight gain, lipid, glucose, and prolactin level abnormalities) associated with atypical antipsychotic use in children and adolescents aged ≤18 years were included, irrespective of whether the investigation of adverse effects was a primary or secondary endpoint.

Results

We identified 21 studies of drug versus placebo that met the inclusion criteria, with a total of 2,455 patients, 14 studies for risperidone (1,331 patients), three for olanzapine (276 patients), and four for aripiprazole (848 patients). Compared with placebo, the mean weight increases for each drug were olanzapine 3.45 kg (95 % CI 2.93–3.98), risperidone 1.77 kg (95 % CI 1.35–2.20), and aripiprazole 0.94 kg (95 % CI 0.65–1.24). Regarding other metabolic abnormalities, eight studies reported statistically significant increases in prolactin with risperidone; two reported a statistically significant increase in glucose, total cholesterol, and prolactin with olanzapine; and three studies reported a statistically significant decrease in prolactin with aripiprazole. Data on lipid, glucose, and prolactin level changes were too limited to allow us to perform a meta-analysis.

Conclusions

Olanzapine, risperidone, and aripiprazole were all associated with statistically significant weight gain. Olanzapine was associated with the most weight gain and aripiprazole the least. For the secondary outcome, although a number of active comparator trials were identified, data were not available for meta-analysis and were too limited to allow firm conclusions to be drawn.

References

  1. 1.
    Jones P, Barnes TR, Davies L, et al. Randomised controlled trial of the effect of quality of life of second vs. first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006;63:1079–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in treatment of children and adolescents. Psychiatr Serv. 1999;50:171–4.PubMedGoogle Scholar
  3. 3.
    Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behaviour disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Glick I, Murray S, Hu R, et al. Treatment with atypical antipsychotics: new indications and new population. J Psychiatr Res. 2001;35:187–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Nasrallah N. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28:83–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Findling RL, Robb A, Nyilas M, et al. A multiple-centre, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165:1432–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder. Am J Psychiatry. 2008;165:1420–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry. 2008;69(suppl.4):4–8.PubMedGoogle Scholar
  9. 9.
    Kryzhanovskaya LA, Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70:247–58.PubMedCrossRefGoogle Scholar
  10. 10.
    Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systemic review and pooled analysis of short term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Wong ICK, Murray ML, Camilleri-Novak D, et al. Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child. 2004;89:1131–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Rani F, Byrne PJ, Murray ML, Wong ICK, et al. Epidemiological features of antipsychotics prescribing to children and adolescents in primary care in United Kingdom. Pediatrics. 2008;121:1002–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Martin A, Leslie D. Trends in psychotropic medications costs for children and adolescents, 1997–2000. Arch Pediatr Adolesc Med. 2003;157:997–1004.PubMedCrossRefGoogle Scholar
  14. 14.
    Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol. 2001;39:1–14.CrossRefGoogle Scholar
  15. 15.
    Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480–91.PubMedGoogle Scholar
  16. 16.
    Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Fleischhaker C, Heister P, Hennighausen K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16:308–16.PubMedCrossRefGoogle Scholar
  18. 18.
    Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public health crisis common sense cure. Lancet. 2002;360:473–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Lissau I, Sorensen TI. Parental neglect during childhood and increased risk of obesity in young adulthood. Lancet. 1994;343:324–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Srinivasan SR, Myers L, Berenson G. Predictability of childhood adiposity and insulin for developing Insulin resistance syndrome in young adulthood. The Bogalusa Heart Study. Diabetes. 2002;51:204–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Johonson JG, Cohen P, Kasen S, et al. Childhood adversities associated with the risk for eating disorder or weight problems during adolescents or early adulthood. Am J Psychiatry. 2002;159:394–400.CrossRefGoogle Scholar
  22. 22.
    Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Almandil NB, Wong ICK. Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed. 2011;96:192–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;159:1686–96.Google Scholar
  26. 26.
    Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Pringsheim T, Lam D, Ching H, Pattens S. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomised controlled trials. Drug Saf. 2011;34(8):651–68.PubMedCrossRefGoogle Scholar
  28. 28.
    De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144–58.PubMedCrossRefGoogle Scholar
  29. 29.
    Egger M, Smith GB, Altman D. Systemic review in health care: meta-analysis in context. London: BMJ Publishing Group; 2001. p. 23–66.CrossRefGoogle Scholar
  30. 30.
    Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–900.PubMedCrossRefGoogle Scholar
  31. 31.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomised clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.Google Scholar
  33. 33.
    Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18:140–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Scahill L, Leckman JF, Schultz RT, et al. A placebo controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Spettigue W, Buchholz A, Henderson K, et al. Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial. BMC Pediatr. 2008;8:4.PubMedCrossRefGoogle Scholar
  36. 36.
    Delbello MP, Schwiers ML, Rosenberg HL, et al. A double blind randomised placebo controlled study of quetiapine as adjunctive treatment of adolescent mania. Psychiatry. 2002;41:1216–23.Google Scholar
  37. 37.
    Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:509–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239–48.PubMedCrossRefGoogle Scholar
  39. 39.
    Van Bellinghen M, De Troch C. Risperidone in the treatment of disturbances in children and adolescents with borderline intellectual functioning: a double-blind placebo controlled trial. J Child Adolesc Psychopharmacol. 2001;11:5–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026–36.PubMedCrossRefGoogle Scholar
  41. 41.
    Aman MG, DeSmedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337–46.PubMedCrossRefGoogle Scholar
  42. 42.
    McCracken JT, McGough J, Shah B, etal.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–21.Google Scholar
  43. 43.
    Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163:402–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Nagaraj R, Shinghi P, Malhi P. Risperidone in children with autism: randomised, placebo-controlled, double blind study. J Child Neurol. 2006;21(6):450–5.PubMedGoogle Scholar
  46. 46.
    Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46:558–65.PubMedCrossRefGoogle Scholar
  47. 47.
    Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16:575–87.PubMedCrossRefGoogle Scholar
  49. 49.
    Haas M, Unis AS, Armenteros J, et al. A 6 week randomized double blind placebo controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611–21.PubMedCrossRefGoogle Scholar
  50. 50.
    Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized double blind placebo controlled study. Bipolar Disord. 2009;11(11):687–700.PubMedCrossRefGoogle Scholar
  51. 51.
    Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16:541–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547–56.PubMedCrossRefGoogle Scholar
  53. 53.
    Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6 week randomised double blind placebo controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder co-morbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–40.PubMedCrossRefGoogle Scholar
  56. 56.
    Marcus RN, Owen R, Kamen L, et al. A placebo controlled fixed does study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Barzman DH, Delbello MP, Adler CM, et al. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsive and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16:665–70.PubMedCrossRefGoogle Scholar
  58. 58.
    Keefe R, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;166:985–95.CrossRefGoogle Scholar
  59. 59.
    Buchsbaum MS, Haznedar MM, Aronowitz J, et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res. 2007;94:293–305.PubMedCrossRefGoogle Scholar
  60. 60.
    Emsley RA, Risperidone working group. Risperidone in the treatment of first episode psychotic patients: a double blind multicentre study. Schizophr Bull. 1999;25:721–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Emsley R, Rabinowitz J, Medori R, et al. Remission in early psychosis: rates, predictors and clinical and functional outcome correlates. Schizophr Res. 2007;89:129–39.PubMedCrossRefGoogle Scholar
  62. 62.
    Facorro BC, Iglesias RP, Bonilla MR, et al. A practical clinical trial comparing haloperidol, risperidone and olanzapine for acute treatment of first episode nonaffective psychosis. J Clin Psychiatry. 2006;67:1511–21.CrossRefGoogle Scholar
  63. 63.
    Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008;18:307–16.PubMedCrossRefGoogle Scholar
  64. 64.
    Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):26–36.PubMedGoogle Scholar
  66. 66.
    Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Inter Clin Psychopharmacol. 2001;16:197–203.CrossRefGoogle Scholar
  67. 67.
    Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Beasley CM, Sutton VK, Hamilton SH, et al. A double blind randomized placebo controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23:582–94.PubMedCrossRefGoogle Scholar
  69. 69.
    Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337–43.PubMedCrossRefGoogle Scholar
  70. 70.
    Ross RG, Novins D, Farley GK, et al. A 1-year open label trial of olanzapine in school age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13:301–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Haapasalo-Pesu KM, Saarijärvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur Child Adolesc Psychiatry. 2001;10:205–8.PubMedCrossRefGoogle Scholar
  72. 72.
    National Institute for Health and Clinical Excellence (NICE). Mental health and behavioural disorders. London: NICE; 2006.Google Scholar
  73. 73.
    Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009; (4): CD006569.Google Scholar
  74. 74.
    Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction on aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Aitchison KJ, Mir A, Shivakumar K, et al. Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. J Psychopharmacol. 2011;25(5):675–84. doi:10.1177/0269881109358198.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Noor B. Almandil
    • 1
  • Ying Liu
    • 1
    • 2
  • Macey L. Murray
    • 1
  • Frank M. C. Besag
    • 1
    • 3
  • Katherine J. Aitchison
    • 4
    • 5
  • Ian C. K. Wong
    • 1
    • 2
  1. 1.Centre for Paediatric Pharmacy Research, University College London School of PharmacyLondonUK
  2. 2.Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, 21 Sassoon Road, 2/F Laboratory Block, Li Ka Shing Faculty of MedicineUniversity of Hong KongHong Kong SARChina
  3. 3.Child and Adolescent Mental Health Service, Children’s Learning Disability Team, SEPT: South Essex Partnership NHS TrustBedfordUK
  4. 4.Alberta Centennial Addiction and Mental Health Research Chair, Department of Psychiatry, 5-142 Katz Group CentreUniversity of AlbertaEdmontonCanada
  5. 5.Institute of Psychiatry, MRC SGDP Centre, King’s College LondonLondonUK

Personalised recommendations